

SUBFUND OVERVIEW

The fund's objective is to generate long-term capital appreciation by investing in a global portfolio composed principally of convertible bonds without any geographical or currency limitation. Convertible bonds are sensitive to movements in equities, credit, interest rates and volatility. Thus, according to the manager's macroeconomic assumptions, the portfolio parameters are set, with a bond or an equity bias. Thereafter, a selection process picks and weights around 50 to 60 investments to structure the portfolio. The fund is not benchmarked.

INVESTMENT MANAGER'S COMMENTS

June 2016 will remain eponymous of the vote for Brexit, even if nothing is actually done yet! Management, as a good housekeeper, means we do not speculate on a referendum outcome. Thus we had kept some dry powder and took advantage of the early market turmoil to take some positions. But let's be clear, low/negative rates and volatility are here to stay. Therefore, our long-term stock-picking approach through convertible bonds is of great interest in the actual environment because if equity investment makes sense with a negative Bund rate, you need the convertible bond floor to smooth volatility.

Also, it is a great opportunity to invest into convertibles that have experienced a significant valuation decline in the last months: almost half of European convertibles were overvalued in October 2015 (convertible bond volatility being superior by 8% on average compare to the underlying equity) while now over 40% have a negative volatility spread.

As an illustration, we bought back **Azimut 2.125% 2020** on the cheap (25% implied volatility and 1% yield to maturity) after having sold it in December 2015 with an implied volatility of 40% and a negative yield. We like the company, and its ratchet clause in a sector which is concentrating.


Also, we participated in an interesting primary issue: **BAM**, a Dutch construction group whose origins date back to 1869 (42% Construction, 50% civil engineering (roads, tunnels etc.), 6% infrastructure

management, 2% public-private partnership). Its equity/total balance sheet ratio was of 21% with a net cash position of EUR 40 million. The convertible's profile is mixed-bond with a yield of 3.3% coupled with an equity sensitivity of 42%. Valuation is distressed with a theoretical price of 5% above the market price. Among all the convertibles issued this year, it is the profile paying the highest rate coupon (3.5%). Furthermore, ten of the eleven brokers following the company have a positive recommendation with an average target price increase of 45%.

LinkedIn, the largest database of business professionals, has been acquired by Microsoft. Again, we invested in a Unicorn company and the 49% premium paid on the last price for this all cash purchase illustrates how sometimes you have to be patient for the price of a security to reach its value.

Following that, our investment into **Allergan** has still not started to bear fruit, but be patient; beautiful flowers do not bloom immediately. Merrill Lynch just added it to its best investment ideas drawn from the universe of Buy rated US listed stocks with a goal of providing superior investment performance over the long term. For the analyst, Mr. Kulkarni, the nearly 30% decline year to date is due to the failed Pfizer merger but provides a great opportunity with many short-term catalysts.

NAV PER SHARE SINCE INCEPTION (CLASS A)



PERFORMANCE


	A	C	H
DELTA	45%	45%	19%
VOLATILITY	10.89%	8.15%	5.09%
NAV/SHARE	130.52	104.19	105.38
MONTH	-1.20%	-1.76%	-1.04%
2016	-4.95%	-4.24%	-5.11%
2015	4.69%	-1.58%	0.95%
2014	14.17%	5.59%	9.85%
2013	3.88%	7.63%	0.15% *
2012	4.66%	1.40%	
2011	-12.34%	-7.26%	

* Since 01/07/2013


MAIN HOLDINGS

TOP 10	CCY	MATURITY / DURATION	PUT	%	DELTA	YTM/YTP	TOP 5 / BOTTOM 5 (ATTRIBUTION)
POST HOLDING 2.5% 2049	USD			3.51%	97%	1.56%	POST HOLDING 2.5% 2049 0.29%
TAKE-TWO INTERACTIVE 1% 2018	USD	01/07/18		3.28%	97%	0.00%	REMGRO JERSEY 2.625% 2021 0.13%
ALLERGAN PLC 5.5% 2018	USD	01/03/2018		3.05%	72%	6.67%	BANK OF AMERICA CORP 7.25% 2049 0.07%
TEVA PHARMA C 0.25% 2026	USD	01/02/26	01/02/16	2.32%	100%	0.00%	ROYAL GOLD 2.875% 2019 0.06%
BANK OF AMERICA CORP 7.25% 2049	USD			2.19%	25%	0.00%	LINKEDIN 0.5% 2019 0.05%
PARPUBLICA / GALP 5.25% 2017	EUR	28/09/17	28/09/15	2.11%	36%	1.50%	
AMERICA MOVIL 0% 2020	EUR	28/05/2020		2.01%	25%	0.17%	ALLERGAN PLC 5.5% 2018 -0.10%
FORTIS CASHES 2.305% 2049	EUR	29/12/49		1.96%	7%	3.42%	ABLYNX NV 3.25% 2020 -0.11%
ORPEA 1.75% 2020	EUR	01/01/2020		1.90%	83%	0.00%	DEPOMED 2.5% 2021 -0.13%
SIEMENS FINANCIERINGSMAT 1.05% 2017	USD	16/08/2017		1.90%	6%	0.00%	PACIRA PHARMACEUTICALS 3.25% 2019 -0.17%
							TELECOM ITALIA 6.125% 2016 -0.18%
PORTFOLIO		4.36		100%	45%	2.66%	


GEOGRAPHIC ALLOCATION




CURRENCY ALLOCATION



SECTOR ALLOCATION



CREDIT SPREAD



Source: Deutsche Bank

GENERAL INFORMATION

SHARE CLASS	ISIN	LAUNCH DATE	MAN. FEE	PERF. FEE	MIN. INVEST.	CLASS SHARES	SUBFUND ASSETS	CUT-OFF
A	LU0442197868	03/08/2009	1.85%	15% ABOVE 3-MONTHS LIBOR EUR (HIGH WATER MARK)	€ 1.000	CAPITALISATION	EUR 49 MILLIONS	DAILY 12:00 AM
B (INSTITUTIONAL)	LU0518233621	12/07/2010	1.20%		€ 1.000.000			
C (CURRENCY HEDGE)	LU0662027985	16/08/2011	1.85%		€ 1.000			
H (DELTA & CCY HEDGE)	LU0944844058	01/07/2013	1.85%		€ 1.000			

CUSTODIAN	VP Bank (Luxembourg) SA	INVESTMENT MANAGER	Bellatrix Asset Management S.A.
SUBSCRIPTIONS / REDEMP	VP Fund Solution (Luxembourg) SA		31, bd Prince Henri L-1724 Luxembourg
CENTRAL ADMIN / TA	FAX +352 404 770 283 TEL +352 404 770 260 luxfunds@vpbank.com		(+352) 26 25 66 20 info@bellatrix.lu
FUND	HARVEST INVESTMENT FUND 26, Av. de la Liberté L-1930 Luxembourg	ADVISOR	Harvest Advisory S.A.
		AUDITOR	Deloitte Audit S.à.r.l
		LEGAL ADVISOR	Elvinger, Hoss & Prussen

Investment Manager's comments are expressed by Bellatrix Asset Management S.A.. Periodic reports, the prospectus of the Fund, and the simplified prospectus of the subfund are available on request from Bellatrix Asset Management S.A. or at the registered office of the Fund. The present information note should not be considered as an offer to buy or sell shares. In order to constitute an offer, this document should be accompanied by the prospectus of the Fund, the simplified prospectus of the subfund and the latest periodic report. Although they are based on the best possible sources, the figures in this document have not been audited. Past performance is no guarantee of future performance as the net asset value of the portfolio of the subfund depends on market developments. Returns are net of management and performance fees.